clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
| Losurdo G et al. | Role of concomitant therapy for eradication: A technical note. | 2016 | World J. Gastroenterol. | pmid:27784977 |
| Zycinska K et al. | Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. | 2016 | Adv. Exp. Med. Biol. | pmid:27620311 |
| Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
| Hirata Y et al. | Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. | 2016 | Int. J. Infect. Dis. | pmid:27590563 |
| Liou JM et al. | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | 2016 | Lancet | pmid:27769562 |
| Campillo A et al. | [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. | 2016 | Gastroenterol Hepatol | pmid:27084668 |
| Zhou L et al. | Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. | 2016 | Helicobacter | pmid:26104022 |
| Watanabe M et al. | Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. | 2016 | Int J Pharm | pmid:27553780 |
| Nagashima A et al. | Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. | 2016 | Antimicrob. Agents Chemother. | pmid:27550358 |
| Couture G et al. | [Second case of serum sickness-like reaction to claritrhomycin]. | 2016 | Presse Med | pmid:27542759 |
| Bugli F et al. | In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. | 2016 | Biotechnol. Prog. | pmid:27535356 |
| Shichijo S et al. | Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. | 2016 | J Dig Dis | pmid:27534444 |
| Morimoto K et al. | Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. | 2016 | Ann Am Thorac Soc | pmid:27513168 |
| Lotfipour F et al. | Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. | 2016 | Drug Res (Stuttg) | pmid:25919643 |
| Abd-Elsalam S et al. | A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. | 2016 | Medicine (Baltimore) | pmid:27310977 |
| De Francesco V et al. | Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. | 2016 | J Gastrointestin Liver Dis | pmid:27308644 |
| Miyaki A et al. | An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. | 2016 | Minerva Gastroenterol Dietol | pmid:27304198 |
| Okano Y et al. | Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. | 2016 | BMC Pulm Med | pmid:27287608 |
| Steurer J | [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. | 2016 | Praxis (Bern 1994) | pmid:27269781 |
| Parize P et al. | Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. | 2016 | J Eur Acad Dermatol Venereol | pmid:25677464 |
| Akram FE et al. | A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). | 2016 | Ann. Clin. Microbiol. Antimicrob. | pmid:27530257 |
| Kim JS et al. | Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. | 2016 | Gut Liver | pmid:27114421 |
| Manniello MD et al. | Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. | 2016 | Eur J Pharm Biopharm | pmid:27106605 |
| Fallone CA et al. | The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. | 2016 | Gastroenterology | pmid:27102658 |
| Bilgilier C et al. | Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. | 2016 | Ann. Hematol. | pmid:27091350 |
| Root AA et al. | Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. | 2016 | Br J Clin Pharmacol | pmid:27090996 |
| Kazama I et al. | Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. | 2016 | Chemotherapy | pmid:27088971 |
| Huynh VA et al. | [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. | 2016 | Ann Dermatol Venereol | pmid:27080820 |
| EmiralioÄŸlu N et al. | Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. | 2016 | J. Trop. Pediatr. | pmid:27080471 |
| Graham DY and Dore MP | Helicobacter pylori therapy: a paradigm shift. | 2016 | Expert Rev Anti Infect Ther | pmid:27077447 |
| Murakami K et al. | Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. | 2016 | Gut | pmid:26935876 |
| Park JY et al. | Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. | 2016 | Dig. Dis. Sci. | pmid:26923948 |
| Guirao-Arrabal E et al. | Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. | 2016 | Rev Esp Quimioter | pmid:26888341 |
| Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
| Chua CS et al. | The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. | 2016 | Int J Food Sci Nutr | pmid:26883189 |
| Meng X et al. | [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. | 2016 | Zhonghua Yi Xue Za Zhi | pmid:26879786 |
| Bakshi SS | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2016 | J Laryngol Otol | pmid:26878377 |
| Trac MH et al. | Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. | 2016 | CMAJ | pmid:26903359 |
| Mukai S et al. | Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. | 2016 | Int. J. Oncol. | pmid:26718641 |
| Hirama T et al. | PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. | 2016 | J. Clin. Microbiol. | pmid:26739154 |
| Radheshi E et al. | Postmortem diagnosis of anaphylaxis in presence of decompositional changes. | 2016 | J Forensic Leg Med | pmid:26735898 |
| Hassan ST et al. | In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. | 2016 | Pharm Biol | pmid:26731378 |
| Çağan-Appak Y et al. | Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. | 2016 | Turk. J. Pediatr. | pmid:28276208 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Kamiya K et al. | Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. | 2016 | J. Dermatol. | pmid:26508502 |
| Hollitt A et al. | Cat scratch disease of the parotid gland. | 2016 | Arch. Dis. Child. | pmid:26403943 |
| Oh B et al. | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. | 2016 | Helicobacter | pmid:26395781 |
| Lee J et al. | A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. | 2016 | J. Matern. Fetal. Neonatal. Med. | pmid:26373262 |
| Tsujimae M et al. | A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. | 2016 | Digestion | pmid:28030862 |